The Life-long Care of Individuals with Lennox-Gastaut Syndrome: Strategies for Outcomes Optimization from Childhood Through Adulthood - CME Outfitters Medical Education

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Meet the Faculty:

Introduction:

April 5, 2025:

Abstracts:

Disruptive Impacts of Developmental and Epileptic Encephalopathies on Patient and Family Life: a Quality-of-Life Survey

Caregiver-Reported Real-world Use of Cannabidiol (CBD) and Effects on Seizures and Caregiver Burden: Results From the CARE-EpiC Survey

April 6, 2025:

Abstracts:

Nurse-Reported Outcomes of Cannabidiol (CBD) Treatment in the Long-Term Care (LTC) Setting: Results From the BEhavior, COgnition, and More With Epidiolex® in the Long-Term Care Setting (BECOME-LTC) Survey

Beyond Dravet and Lennox-Gastaut Syndrome: Evaluating Cannabidiol’s Role in Drug-Resistant Epilepsy Treatment

April 7th, 2025:

Abstracts:

Understanding the Incidence, Prevalence, Characteristics, and Healthcare Resource Utilization for Patients With Dravet and Lennox-Gastaut Syndromes

A Retrospective Claims Study Evaluating Mortality in Patients With Lennox-Gastaut or Dravet Syndromes in the United States

April 8th, 2025:

Abstracts:

Safety and Effectiveness of Fenfluramine for the Treatment of Seizures in Lennox-Gastaut Syndrome: Results From the Final Analysis of an Open-Label Extension Study

A 20-Week Multicenter, Randomized, Double-Blind (DB), Placebo-Controlled, Phase 3 Trial (EPX 100-003) of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in patients with Lennox-Gastaut Syndrome (LGS)